Clinical Trials · NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Ohio State University
- Enrollment
- 23,280,000
- Start date
- Sep 2025
- Locations
- 1 site, United States
- Primary endpoint
- 3-Point major adverse cardiovascular event (3P-MACE)